Business Context and Reporting Period
This Form 8-K filing by Phathom Pharmaceuticals, Inc. (PHAT) reports a significant executive appointment effective October 6, 2025. The report was filed on October 2, 2025, under Item 5.02 regarding the departure of directors or certain officers and the appointment of certain officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
Material Changes
Executive Leadership Change: Sanjeev Narula was appointed as Chief Financial and Business Officer and Principal Financial Officer, replacing Robert Breedlove (who remains Principal Accounting Officer).
Compensation Structure: Mr. Narula's initial annual base salary is set at $550,000 with a target annual bonus of 50% of base salary.
Outlook, Risks, and Unusual Items
Equity Grants: Upon commencement, Mr. Narula received:
- 200,000 stock options vesting over four years (25% on first anniversary, remainder monthly).
- 144,000 restricted stock units (RSUs) vesting over three years in equal annual installments.
- Standard Termination: 9 months of base salary, prorated target bonus, COBRA coverage, and accelerated vesting of time-based equity for the 9-month period.
- Change in Control Termination: 18 months of base salary, 1.5x target bonus, COBRA coverage, and full acceleration of all unvested time-based equity.
Investor Verification Checklist
- Verify the exact closing price of PHAT stock on October 6, 2025, to determine the exercise price of the 200,000 stock options granted.
- Review the Company's 2019 Incentive Award Plan to confirm the terms governing performance-based vesting conditions.
- Assess the impact of the new CFO's background (formerly Intra-Cellular Therapies, Viatris, Pfizer) on the Company's financial strategy and operational oversight.
- Monitor future filings for any changes to the Company's liquidity position or capital needs following this leadership transition.